Who
Christopher Horan
Chief Tech Operations Officer
Company insider
Files Form 4 as: Chief Tech Operations Officer, Artiva Biotherapeutics; Chief Technical Ops Officer, Dermira.
In numbers
- Trades disclosed
- 34
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $428K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 7 May 2018
- Last trade
- 5 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 May – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 6 Oct 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $71K10,340 at $6.84 | filing |
| 9 Sep 2026filed 11 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Sep 2026filed 11 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 9 Sep 2026filed 11 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 9 Sep 2026filed 11 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 3 Sep 2026filed 4 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $116K10,366 at $11.16 | filing |
| 3 Sep 2026filed 4 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $116K10,366 at $11.16 | filing |
| 19 May 2026filed 19 May 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $63K7,002 at $9.01 | filing |
| 19 May 2026filed 19 May 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $63K7,002 at $9.01 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —117,300 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $8,7482,187 at $4.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —117,300 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $8,7482,187 at $4.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —77,519 | filing |
| 12 Dec 2025filed 12 Dec 2025 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —9,119 | filing |
| 12 Dec 2025filed 12 Dec 2025 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,519 | filing |
| 12 Dec 2025filed 12 Dec 2025 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —107,156 at $0.00 | filing |
| 15 Nov 2025filed 17 Nov 2025 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $6,1721,899 at $3.25 | filing |
| 15 Aug 2025filed 18 Aug 2025 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $9,8373,577 at $2.75 | filing |
| 15 May 2025filed 18 Aug 2025 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $2,8561,341 at $2.13 | filing |
News
No headline names them, or the companies they trade most, lately.